View Future GrowthNational Peroxide 과거 순이익 실적과거 기준 점검 2/6지난 몇 년간 National Peroxide 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Chemicals 산업 성장률17.68%매출 성장률0.99%자기자본이익률3.05%순이익률3.81%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.공고 • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).공고 • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).공고 • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jun 05Now 20% undervaluedOver the last 90 days, the stock has risen 35% to ₹560. The fair value is estimated to be ₹704, however this is not to be taken as a buy recommendation but rather should be used as a guide only.New Risk • May 27New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 1.2% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Market cap is less than US$100m (₹3.38b market cap, or US$35.3m).Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).공고 • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).공고 • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).공고 • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025공고 • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.공고 • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).공고 • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025공고 • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.공고 • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025공고 • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024공고 • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.공고 • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.공고 • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024매출 및 비용 세부 내역National Peroxide가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BSE:544205 매출, 비용 및 순이익 (INR Millions)날짜매출순이익일반관리비연구개발비31 Mar 262,897110265031 Dec 252,777-34258030 Sep 252,708-67276030 Jun 252,795-64296031 Mar 252,869-22304031 Dec 243,01273313031 Mar 243,3301682930양질의 수익: 544205는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 544205는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 544205의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 544205는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: 544205는 지난해 흑자전환하여 지난 해 수익 성장률을 Chemicals 업계(13.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 544205의 자본 수익률(3%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 18:20종가2026/07/13 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스National Peroxide Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.
공고 • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).
공고 • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).
공고 • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025
Buy Or Sell Opportunity • Jun 05Now 20% undervaluedOver the last 90 days, the stock has risen 35% to ₹560. The fair value is estimated to be ₹704, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
New Risk • May 27New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 1.2% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Market cap is less than US$100m (₹3.38b market cap, or US$35.3m).
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.
New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).
공고 • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).
공고 • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).
공고 • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025
공고 • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.
Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.
공고 • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).
공고 • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025
공고 • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.
공고 • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025
공고 • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024
공고 • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.
공고 • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.
공고 • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024